Download Financial/Commercial Relationships DISCLOSURES

Name of Reviewer(s):
Laurie Gaspar, MD –Nothing to Disclose
Name of Planner(s):
Carlos Ferreira
Pia Hirsch-Nothing to Disclose
Carlos Ferreira-Nothing to Disclose
Name of Activity:
Locally Advanced NSCLC: Where Are We, Where Do We Go From Here?
Date of Activity:
05/09/2017
Faculty/Speaker(s)Disclosure:
COI Resolution: Ensure a
balanced discussion of
alternative. Do not use trade
names. Do not refer to company
names or logos. Do not
recommend therapies.
Chair: Ramaswamy Govindan, MD
Honoraria:
ABBVIE, ARIAD, AZ, BAXALTA, BMS, MERCK, ROCHE
Nothing to Disclose
Speaker: Everett Vokes, MD
Consultant/Advisory Board for: Consultant/Advisory Role: AbbVie, Amgen,
AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Genentech, Leidos,
Merck, Regeneron, Serono, Takeda, VentiRx.
“All planning committee
members’, reviewers, planners
and faculty et al. identified
conflicts of interest pertaining to
this activity were resolved prior
to the activity.”
Type of Activity:
Are there Commercial
Supporters for this activity?
Live Course
Yes
No
Internet Live Course (Webinar)
Internet Enduring Material
If yes, please list:
Financial/Commercial Relationships DISCLOSURES
A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of
CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12
months with a commercial interest that produces, markets, re-sells, or distributes health care goods or
services consumed by, or used, on patients that benefits the individual in any financial amount and
therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual
property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other
ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits
are usually associated with roles such as employment, management position, independent contractor
(including contracted research and clinical trials), consulting, speaking and teaching, membership on
advisory committees or review panels, board membership, and other activities for which remuneration is
received or expected.
This IASLC CME educational activity was planned and developed to: uphold academic standards to
ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health
information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include
a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents
are discussed or referenced.
IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest
were identified, reviewed and resolved from all individuals involved in the development or able to influence
and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an
educational activity being delivered to learners. Any individual who failed or refused to disclose
relevant financial relationships was disqualified from this CME activity and removed from any of IASLC
CME activity presentation.
All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC
Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of
Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient
care recommendations. IASLC CME is committed to providing its learners with high-quality CME
activities and related materials that promote improvements or quality in health care and not a specific
proprietary business interest of a commercial entity.
The following Financial Disclosures are from the, reviewers and planning committee members (et.al.)
their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any
commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients
that are relevant to this presentation(s) or that have provided commercial support for this continuing
medical education activity: HAVE NOTHING TO DISCLOSE.
Speakers Financial Disclosures:
Chair: Ramaswamy Govindan, MD
Honoraria: ABBVIE, ARIAD, AZ, BAXALTA, BMS, MERCK, ROCHE
Speaker: Everett Vokes, MD
Consultant/Advisory Role: AbbVie, Amgen, AstraZeneca, BMS,
Boehringer-Ingelheim, Celgene, Eli Lilly, Genentech, Leidos, Merck, Regeneron, Serono, Takeda,
VentiRx.
Consultant/Advisory Board for:
CREDIT STATEMENT
IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide
continuing medical education for physicians.
IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1
Credits™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
FINANCIAL SUPPORT
No Commercial Support was provided for this activity.
GOAL & PURPOSE
In this program, we will:

Aid practicing oncologists in the standard of care management of patients with locally advanced
(Stage III)

Provide clinicians with the rationale for clinical trials evaluating the addition of novel
therapeutic agents specifically, immunotherapies and targeted biologic agents

Aid clinicians in the identification of patients who may candidates for clinical trials

Identify ongoing and planned clinical trials as potential treatment options for patients.
TARGET AUDIENCE
This CME live webinar series is designed to meet the educational needs of healthcare professionals who
diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons,
pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and
physicians' assistants.
LEARNING OBJECTIVES

Increase clinician awareness of novel immunotherapeutic and targeted biologic agents
that have demonstrated activity in stage IV NSCLC and may be appropriate candidates
for clinical trials in earlier stages of disease.

Review current management of stage III NSCLC, including combined modality
approaches and the potential use of immunotherapy, or targeted biologic agents.

Identify ongoing clinical trials that are likely to impact patient care in the near future.
DISCLAMER
Participants have an implied responsibility to use the newly acquired information to enhance patient
outcomes and their own professional development. The information presented in this activity is not
meant to serve as a guideline for patient management. Any procedures, medications, or other courses of
diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any
applicable manufacturer’s product information, and comparison with recommendations of other
authorities.
Thank you for your participation.